COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron)

Wan Yang[1*] and Jeffrey Shaman[2]

[1]Department of Epidemiology, [2]Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA

*Correspondence to: wy2202@cumc.columbia.edu

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) have been key drivers of new coronavirus disease 2019 (COVID-19) pandemic waves. To better understand variant epidemiologic characteristics, here we apply a model-inference system to reconstruct SARS-CoV-2 transmission dynamics in South Africa, a country that has experienced three VOC pandemic waves (i.e. Beta, Delta, and Omicron). We estimate key epidemiologic quantities in each of the nine South African provinces during March 2020 – Feb 2022, while accounting for changing detection rates, infection seasonality, nonpharmaceutical interventions, and vaccination. Model validation shows that estimated underlying infection rates and key parameters (e.g., infection-detection rate and infection-fatality risk) are in line with independent epidemiological data and investigations. In addition, retrospective predictions capture pandemic trajectories beyond the model training period. These detailed, validated model-inference estimates thus enable quantification of both the immune erosion potential and transmissibility of three major SARS-CoV-2 VOCs, i.e., Beta, Delta, and Omicron. These findings help elucidate changing COVID-19 dynamics and inform future public health planning.

Keywords: COVID-19, SARS-CoV-2, variant of concern, immune evasion, transmissibility

INTRODUCTION

Since its emergence in late December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing the coronavirus disease 2019 (COVID-19) pandemic (1). In just two years, SARS-CoV-2 has caused several pandemic waves in quick succession in many places. Many of these repeated pandemic waves have been driven by new variants of concern (VOCs) or interest (VOIs) that erode prior immunity from either infection or vaccination, increase transmissibility, or a combination of both. However, while laboratory and field studies have provided insights into these epidemiological characteristics, quantifying the extent of immune erosion (or evasion) and changes to transmissibility for each VOC remains challenging.

37
Like many places, by February 2022 South Africa had experienced four distinct pandemic waves
caused by the ancestral SARS-CoV-2 and three VOCs (Beta, Delta, and Omicron). However,
South Africa is also unique in that the country had the earliest surge for two of the five VOCs
identified to date – namely, Beta (2) and Omicron (3). To better understand the COVID-19
dynamics in South Africa and variant epidemiological characteristics, here we utilize a model-
inference system similar to one developed for study of SARS-CoV-2 VOCs, including the Beta
variant in South Africa (4). We use this system to reconstruct SARS-CoV-2 transmission
dynamics in each of the nine provinces of South Africa from the pandemic onset during March
2020 to the end of February 2022 while accounting for multiple factors modulating underlying
transmission dynamics. We then rigorously validate the model-inference estimates using
independent data and retrospective predictions. The validated estimates quantify the immune
erosion potential and transmissibility of three major SARS-CoV-2 variants, i.e., Beta, Delta, and
Omicron, in South Africa. Our findings highlight several common characteristics of SARS-CoV-2
VOCs and the need for more proactive planning and preparedness for future VOCs, including
development of a universal vaccine that can effectively block SARS-CoV-2 infection as well as
prevent severe disease.
54
RESULTS
Model fit and validation
The model-inference system uses case and death data to reconstruct the transmission
dynamics of SARS-CoV-2, while accounting for under-detection of infection, infection
seasonality, implemented nonpharmaceutical interventions (NPIs), and vaccination (see
Methods). Overall, the model-inference system is able to fit weekly case and death data in each
of the nine South African provinces (Fig 1A and Fig S1). We first validated the model-inference
estimates using three independent datasets. First, we used serology data. We note that early in
the pandemic serology data may reflect underlying infection rates but later, due to waning
antibody titers and reinfection, likely underestimate infection. Compared to seroprevalence
measures taken at multiple time points in each province, our model estimated cumulative
infection rates roughly match corresponding serology measures and trends over time; as
expected, model estimates were higher than serology measures taken during later months (Fig
1B). Second, compared to hospital admission data, across the nine provinces, model estimated
infection numbers were well correlated with numbers of hospitalizations for all four pandemic
waves caused by the ancestral, Beta, Delta, and Omicron variants, respectively ($r > 0.75$, Fig S2
A-D). Third, model-estimated infection numbers were correlated with age-adjusted excess
mortality for both the ancestral and Delta wave ($r = 0.86$ and 0.61, respectively; Fig S2 A and C).
For the Beta wave, after excluding Western Cape, a province with a very high hospitalization
rate but low excess mortality during this wave (Fig S2 B), model-estimated infection numbers

were also correlated with age-adjusted excess mortality for the remaining provinces ($r = 0.55$;

Fig S2 B). For the Omicron wave, like many other places, due to prior infection and/or

vaccination (5, 6), mortality rates decoupled from infection rates (Fig S2 D). Overall,

comparisons with the three independent datasets indicate our model-inference estimates align

with underlying transmission dynamics.

In addition, as a fourth model validation, we generated retrospective predictions of the Delta

and Omicron waves at two key time points, i.e. 2 weeks and 1 week, separately, before the

observed peak of cases (approximately 3 to 5 weeks before the observed peak of deaths; Fig 2).

To accurately predict a pandemic wave caused by a new variant, the model-inference system

needs to accurately estimate the background population characteristics (e.g., population

susceptibility) before the emergence of the new variant, as well as changes in population

susceptibility and transmissibility due to the new variant. This is particularly challenging for

South Africa, as the pandemic waves there tended to progress quickly, with cases surging and

peaking within 3 to 7 weeks before declining. As a result, often only 1 to 6 weeks of new variant

data were available for model-inference before generating the prediction. Despite these

challenges, 1-2 weeks before the case peak and 3-5 weeks before the observed death peak, the

model was able to accurately predict the remaining trajectories of cases and deaths in most of

the nine provinces for both the Delta and Omicron waves (Fig 2 for the four most populous

provinces and Fig S3 for the remainder). These accurate model predictions further validate the

model-inference estimates.

Pandemic dynamics and key model-inference, using Gauteng province as an example

Next, we use Gauteng, the province with the largest population, as an example to highlight

pandemic dynamics in South Africa thus far and develop key model-inference estimates (Fig 3

for Gauteng and Figs S4-S11 for each of the other eight provinces). Despite lower cases per

capita than many other countries, infection numbers in South Africa were likely much higher

due to under-detection. For Gauteng, the estimated infection-detection rate during the first

pandemic wave was 4.59% (95% CI: 2.62 – 9.77%), and increased slightly to 6.18% (95% CI: 3.29

– 11.11%) and 6.27% (95% CI: 3.44 – 12.39%) during the Beta and Delta waves, respectively

(Table S1). These estimates are in line with serology data. In particular, a population-level sero-

survey in Gauteng found 68.4% seropositivity among those unvaccinated at the end of the Delta

wave (7). Combining the reported cases at that time (~6% of the population size) with

undercounting of infections in sero-surveys due to sero-reversions and reinfections suggests

that the overall detection rate would be less than 10%.

Using our inferred under-detection (Fig 3E), we estimate that 32.83% (95% CI: 15.42 - 57.59%,

Table S2) of the population in Gauteng were infected during the first wave, predominantly

during winter when more conducive climate conditions and relaxed public health restrictions
existed (see the estimated seasonal and mobility trends, Fig 3A). This high infection rate, while
with uncertainty, is in line with serology measures taken in Gauteng at the end of the first wave
(ranging from 15% to 27% among 6 sero-surveys during November 2020; Fig 1B) and a study
showing 30% sero-positivity among participants enrolled in the Novavax NVX-CoV2373 vaccine
phase 2a-b trial in South Africa during August – November 2020 (8).
119
With the emergence of Beta, another 21.87% (95% CI: 12.16 – 41.13%) of the population in
Gauteng – including reinfections – is estimated to have been infected, even though the Beta
wave occurred during summer under less conducive climate conditions for transmission (Fig
3A). Consistent with laboratory studies showing low neutralizing ability of convalescent sera
against Beta (9, 10), the model-inference system estimates a large increase in population
susceptibility with the surge of Beta (Fig 3D). In addition to this immune erosion, an increase in
transmissibility is also evident for Beta, after accounting for concurrent NPIs and infection
seasonality (Fig 3C). Notably, in contrast to the large fluctuation of the time-varying effective
reproduction number over time (R_t, Fig 3B), the transmissibility estimates are more stable and
reflect changes in variant-specific properties. Further, consistent with in-depth epidemiological
findings (11), the estimated overall infection-fatality risk for Beta was about twice as high as the
ancestral SARS-CoV-2 (0.19% [95% CI: 0.10 - 0.33%] vs. 0.09% [95% CI: 0.05 - 0.20%], Fig 3F and
Table S3). Nonetheless, these estimates are based on documented COVID-19 deaths and are
likely underestimates.
134
With the introduction of Delta, a third pandemic wave occurred in Gauteng during the 2021
winter. The model-inference system estimates a 49.82% (95% CI: 25.22 – 90.79%) attack rate by
Delta, despite the large number of infections during the previous two waves. This large attack
rate was possible, due to the high transmissibility of Delta, as reported in multiple studies (12-
16), the more conducive winter transmission conditions (Fig 3A), and the immune erosion from
Delta relative to both the ancestral and Beta variants (17-19).
141
Due to these large pandemic waves, prior to the detection of Omicron in Gauteng, estimated
cumulative infection numbers surpassed the population size (Fig 4B), indicating the large
majority of the population had been infected and some more than once. With the rise of
Omicron, the model-inference system estimates a very large increase in population
susceptibility (Fig 3D), as well as an increase in transmissibility (Fig 3C); however, unlike
previous waves, the Omicron wave progresses much more quickly, peaking 2-3 weeks after
initiating marked exponential growth. These estimates suggest that several additional factors
may have also contributed to the observed dynamics, including changes to the infection-
detection rate (Fig 3E), a summer seasonality increasingly suppressing transmission as the wave

progressed (Fig 3A), as well as a slight change in population mobility suggesting potential
behavior changes (Fig 3A). By the end of February 2022, the model-inference system estimates
a 44.49% (95% CI: 19.01 – 75.30%) attack rate, with only 4.26% (95% CI: 2.46 – 9.72%) of
infections detected as cases, during the Omicron wave in Gauteng. In addition, consistent with
the reported 0.3 odds of severe disease compared to Delta infections (6), estimated overall
infection-fatality risk during the Omicron wave was about 30% of that during the Delta wave in
Gauteng (0.03% [95% CI: 0.02 – 0.06%] vs. 0.11% [95% CI: 0.06 – 0.21%], based on documented
COVID-19 deaths; Table S3).
159
Model inferred epidemiological characteristics across the nine provinces in South Africa
Across all nine provinces in South Africa, the pandemic timing and intensity varied (Fig 4 A-C).
In addition to Gauteng, high cumulative infection rates during the first three pandemic waves
are also estimated for Western Cape and Northern Cape (Fig 1 C-E, Fig 4B and Table S2).
Overall, all nine provinces likely experienced three large pandemic waves prior to the growth of
Omicron; estimated average cumulative infections ranged from 60% of the population in
Limpopo to 122% in Northern Cape (Fig 4B). Corroboration for these cumulative infection
estimates is derived from mortality data. Excess mortality before the Omicron wave was as high
as 0.47% of the South African population by the end of November 2021 (20), despite the
relatively young population (median age: 27.6 years (21) vs. 38.5 years in the US (22)) and thus
lower expected infection-fatality risk (23, 24). Assuming an infection-fatality risk of 0.5% (similar
to estimates in (25) for South Africa), these excess deaths would convert to a 94% infection
rate.
173
Combining these model-inference estimates during each wave in each province, we estimate
that Beta eroded immunity among 63.4% (95% CI: 45.0 – 77.9%) of individuals with prior
ancestral SARS-CoV-2 infection and was 34.3% (95% CI: 20.5 – 48.2%) more transmissible than
the ancestral SARS-CoV-2. These estimates for Beta are consistent across the nine provinces
(Fig 4D, 1st column), as well as with our previous estimates using national data for South Africa
(4). Additional support for the high immune erosion of Beta is evident from recoverees of
ancestral SARS-CoV-2 infection who were enrolled in the Novavax NVX-CoV2373 vaccine phase
2a-b trial (8) and found to have a similar likelihood of COVID-19, mostly due to Beta, compared
to those seronegative at enrollment.
183
Estimates for Delta vary across the nine provinces (Fig 4D, 2nd column), given the more diverse
population immune landscape among provinces after two pandemic waves. Overall, we
estimate that Delta eroded 24.5% (95% CI: 0 – 53.2%) of prior immunity (gained from infection
by ancestral SARS-CoV-2 and/or Beta, and/or vaccination) and was 47.5% (95% CI: 28.4 –
69.4%) more transmissible than the ancestral SARS-CoV-2. Consistent with this finding, and in

particular the estimated immune erosion, studies have reported a 27.5% reinfection rate during
the Delta pandemic wave in Delhi, India (17) and reduced ability of sera from Beta-infection
recoverees to neutralize Delta (18, 19).
192
For Omicron, estimates also vary by province but still consistently point to its higher
transmissibility than all previous variants (Fig 4D, 3ʳᵈ column). Overall, we estimate that
Omicron is 94.0% (95% CI: 73.5 – 121.5%) more transmissible than the ancestral SARS-CoV-2.
This estimated transmissibility is higher than Delta and consistent with *in vitro* and/or *ex vivo*
studies showing Omicron replicates faster within host than Delta (26, 27). In addition, we
estimate that Omicron eroded 54.1% (95% CI: 35.8 – 70.1%) of immunity due to all prior
infections and vaccination. Importantly, we note that the estimate for immune erosion is not
directly comparable across variants, as it is relative to the combined population immunity
accumulated until the rise of each variant. In the case of Beta, it is immunity accumulated from
the first wave via infection by the ancestral SARS-CoV-2. In the case of Omicron, it includes
immunity from prior infection and refection of any of the previously circulating variants as well
as vaccination. Thus, the estimate for Omicron may represent a far broader capacity for
immune erosion than was evident for Beta. Supporting the suggestion of broad-spectrum
immune erosion of Omicron, studies have reported low neutralization ability of convalescent
sera from infections by all previous variants (28, 29), as well as high attack rates among
vaccinees in several Omicron outbreaks (30, 31).
209
DISCUSSION
Using a comprehensive model-inference system, we have reconstructed the pandemic
dynamics in each of the nine provinces of South Africa. Uncertainties exist in our findings, due
to incomplete and varying detection of SARS-CoV-2 infections and deaths, changing population
behavior and public health interventions, and changing circulating variants. To address these
uncertainties, we have validated our estimates using three datasets not used by our model-
inference system (i.e., serology, hospitalization, and excess mortality data; Fig 1B and Fig S2) as
well as retrospective prediction (Fig 2 and Fig S4). In addition, as detailed in the Results, we
have showed that estimated underlying infection rates (Fig 1B and Fig S2) and key parameters
(e.g., infection-detection rate and infection-fatality risk) are in line with other independent
epidemiological data and investigations. The detailed, validated model-inference estimates thus
allow quantification of both the immune erosion potential and transmissibility of three major
SARS-CoV-2 VOCs, i.e., Beta, Delta, and Omicron.
223
Specifically, we make three general observations. First, high prior immunity does not preclude
new outbreaks, as neither infection nor current vaccination is sterilizing. As shown in South
Africa, even with the high infection rate accumulated from preceding waves, new waves can

occur with the emergence or introduction of new variants. Around half of South Africans are
estimated to have been infected after the Beta wave, yet the Delta variant caused a third large
pandemic wave, followed by a fourth wave with comparable infection rates by Omicron (Fig 4B
and Table S2). Second, large numbers of deaths can still occur in later waves with large
infection surges, even though prior infection may provide partial protection and to some extent
temper disease severity. This is evident from the large Delta wave in South Africa, which
resulted in 0.2% excess mortality (vs. 0.08% during the first wave and 0.19% during the Beta
wave (20)). Together, the continued transmission and potential severe outcomes highlight the
importance of continued preparedness and prompt public health actions as societies learn to
live with SARS-CoV-2.
237
Third, multiple SARS-CoV-2 VOCs/VOIs have emerged in the two years since pandemic
inception. It is challenging to predict the frequency and direction of future viral mutation, in
particular, the level of immune erosion, changes in transmissibility, and innate severity.
Nonetheless, given high exposure and vaccination in many populations, variants capable of
eroding a wide spectrum of prior immunity (i.e., from infection by multiple preexisting variants
and vaccination) would have a greater chance of causing new major outbreaks. Indeed, except
for the Alpha variant, the other four important VOCs (i.e. Beta, Gamma, Delta, and Omicron) all
produced some level of immune erosion. In addition, later VOCs, like Delta and Omicron,
appear to have been more genetically distinct from previous variants (32). As a result, they are
likely more capable of causing re-infection despite diverse prior exposures and in turn new
pandemic waves. Given this pattern, to prepare for future antigenic changes from new variants,
development of a universal vaccine that can effectively block SARS-CoV-2 infection in addition
to preventing severe disease (e.g. shown in (33)) is urgently needed (34).
251
252   The COVID-19 pandemic has caused devastating public health and economic burdens
253   worldwide. Yet SARS-CoV-2 will likely persist in the future. To mitigate its impact, proactive
254   planning and preparedness is paramount.
255
METHODS
Data sources and processing
We used reported COVID-19 case and mortality data to capture transmission dynamics,
weather data to estimate infection seasonality, mobility data to represent concurrent NPIs, and
vaccination data to account for changes in population susceptibility due to vaccination in the
model-inference system. Provincial level COVID-19 case, mortality, and vaccination data were
sourced from the Coronavirus COVID-19 (2019-nCoV) Data Repository for South Africa
(COVID19ZA)(35). Hourly surface station temperature and relative humidity came from the
Integrated Surface Dataset (ISD) maintained by the National Oceanic and Atmospheric

Administration (NOAA) and are accessible using the "stationaRy" R package (36, 37). We
computed specific humidity using temperature and relative humidity per the Clausius-
Clapeyron equation (38). We then aggregated these data for all weather stations in each
province with measurements since 2000 and calculated the average for each week of the year
during 2000-2020.
270
Mobility data were derived from Google Community Mobility Reports (39); we aggregated all
business-related categories (i.e., retail and recreational, transit stations, and workplaces) in all
locations in each province to weekly intervals. For vaccination, provincial vaccination data from
the COVID19ZA data repository recorded the total number of vaccine doses administered over
time; to obtain a breakdown for numbers of partial (1 dose of mRNA vaccine) and full
vaccinations (1 dose of Janssen vaccine or 2 doses of mRNA vaccine), separately, we used
national vaccination data for South Africa from Our World in Data (40, 41) to apportion the
doses each day. In addition, cumulative case data suggested 18,586 new cases on Nov 23, 2021,
whereas the South Africa Department of Health reported 868 (42). Thus, for Nov 23, 2021, we
used linear interpolation to fill in estimates for each province on that day and then scaled the
estimates such that they sum to 868.
282

283   **Model-inference system**
284   The model-inference system is based on our previous work estimating changes in
285   transmissibility and immune erosion for SARS-CoV-2 VOCs including Alpha, Beta, Gamma, and
286   Delta (4, 43). Below we describe each component.
287

288   *Epidemic model*
289   The epidemic model follows an SEIRSV (susceptible-exposed-infectious-recovered-susceptible-
290   vaccination) construct per Eqn 1:
291

292
$$\begin{cases} \dfrac{dS}{dt} = \dfrac{R}{L_t} - \dfrac{b_t e_t m_t \beta_t IS}{N} - \varepsilon - v_{1,t} - v_{2,t} \\ \dfrac{dE}{dt} = \dfrac{b_t e_t m_t \beta_t IS}{N} - \dfrac{E}{Z_t} + \varepsilon \\ \dfrac{dI}{dt} = \dfrac{E}{Z_t} - \dfrac{I}{D_t} \\ \dfrac{dR}{dt} = \dfrac{I}{D_t} - \dfrac{R}{L_t} + v_{1,t} + v_{2,t} \end{cases}$$

293
294   where *S*, *E*, *I*, *R* are the number of susceptible, exposed (but not yet infectious), infectious, and
295   recovered/immune/deceased individuals; *N* is the population size; and ε is the number of
296   travel-imported infections. In addition, the model includes the following key components:

1) Virus-specific properties, including the time-varying variant-specific transmission rate β_t, latency period Z_t, infectious period D_t, and immunity period L_t. Note all parameters are estimated for each week (t) as described below.

2) The impact of NPIs. Specifically, we use relative population mobility (see data above) to adjust the transmission rate via the term m_t, as the overall impact of NPIs (e.g., reduction in the time-varying effective reproduction number R_t) has been reported to be highly correlated with population mobility during the COVID-19 pandemic.(44-46) To further account for potential changes in effectiveness, the model additionally includes a parameter, e_t, to scale NPI effectiveness.

3) The impact of vaccination, via the terms $v_{1,t}$ and $v_{2,t}$. Specifically, $v_{1,t}$ is the number of individuals successfully immunized after the first dose of vaccine and is computed using vaccination data and vaccine effectiveness (VE) for 1st dose; and $v_{2,t}$ is the additional number of individuals successfully immunized after the second vaccine dose (i.e., excluding those successfully immunized after the first dose). In South Africa, around two-thirds of vaccines administered during our study period were the mRNA BioNTech/Pfizer vaccine and one-third the Janssen vaccine (47). We thus set VE to 20%/85% (partial/full vaccination) for Beta, 35%/75% for Delta, and 10%/35% for Omicron based on reported VE estimates (48-50).

4) Infection seasonality, computed using temperature and specific humidity data as described previously (see supplemental material of Yang and Shaman(4)). Briefly, we estimated the relative seasonal trend (b_t) using a model representing the dependency of the survival of respiratory viruses including SARS-CoV-2 to temperature and humidity (51, 52). As shown in Fig 2A, b_t estimates over the year averaged to 1 such that weeks with b_t >1 (e.g. during the winter) are more conducive to SARS-CoV-2 transmission whereas weeks with b_t <1 (e.g. during the summer) have less favorable climate conditions for transmission. The estimated relative seasonal trend, b_t, is used to adjust the relative transmission rate at time t in Eqn 1.

Observation model to account for under-detection and delay

Using the model-simulated number of infections occurring each day, we further computed the number of cases and deaths each week to match with the observations, as done in Yang et al (53). Briefly, we include 1) a time-lag from infectiousness to detection (i.e., an infection being diagnosed as a case), drawn from a gamma distribution with a mean of $T_{d,mean}$ days and a standard deviation of $T_{d,sd}$ days, to account for delays in detection (Table S4); 2) an infection-detection rate (r_t), i.e. the fraction of infections (including subclinical or asymptomatic infections) reported as cases, to account for under-detection; 3) a time-lag from infectiousness to death, drawn from a gamma distribution with a mean of 13-15 days and a standard deviation of 10 days; and 4) an infection-fatality risk (IFR_t). To compute the model-simulated number of

new cases each week, we multiplied the model-simulated number of new infections per day by
the infection-detection rate, and further distributed these simulated cases in time per the
distribution of time-from-infectiousness-to-detection. Similarly, to compute the model-
simulated deaths per week and account for delays in time to death, we multiplied the
simulated-infections by the IFR and then distributed these simulated deaths in time per the
distribution of time-from-infectious-to-death. We then aggregated these daily numbers to
weekly totals to match with the weekly case and mortality data for model-inference. For each
week, the infection-detection rate (r_t), the infection-fatality risk (IFR_t)., and the two time-to-
detection parameters ($T_{d,mean}$ and $T_{d,\,sd}$) were estimated along with other parameters (see
below).
345
Model inference and parameter estimation
The inference system uses the ensemble adjustment Kalman filter (EAKF (54)), a Bayesian
statistical method, to estimate model state variables (i.e., *S*, *E*, *I*, *R* from Eqn 1) and parameters
(i.e., β_t, Z_t, D_t, L_t, e_t, from Eqn 1 as well as r_t, IFR_t and other parameters from the observation
model). Briefly, the EAKF uses an ensemble of model realizations (*n*=500 here), each with initial
parameters and variables randomly drawn from a *prior* range (see Table S4). After model
initialization, the system integrates the model ensemble forward in time for a week (per Eqn 1)
to compute the prior distribution for each model state variable and parameter, as well as the
model-simulated number of cases and deaths for that week. The system then combines the
prior estimates with the observed case and death data for the same week to compute the
posterior per Bayes' theorem (54). During this filtering process, the system updates the
posterior distribution of all model variables and parameters for each week.
358
Estimating changes in transmissibility and immune erosion for each variant
As in ref (4), we computed the variant-specific transmissibility (R_{TX}) as the product of the
variant-specific transmission rate (β_t) and infectious period (D_t). Note that R_t, the time-varying
effective reproduction number, is defined as $R_t = b_t e_t m_t \beta_t D_t S/N = b_t e_t m_t R_{TX} S/N$. To
reduce uncertainty, we averaged transmissibility estimates over the period a particular variant
of interest was predominant. To find these predominant periods, we first specified the
approximate timing of each pandemic wave in each province based on: 1) when available,
genomic surveillance data; specifically, the onsets of the Beta wave in Eastern Cape, Western
Cape, KwaZulu-Natal, and Northern Cape, were separately based on the initial detection of Beta
in these provinces as reported in Tegally et al. (2); the onsets of the Delta wave in each of the
nine provinces, separately, were based on genomic sequencing data from the Network for
Genomic Surveillance South Africa (NGS-SA)(55); and 2) when genomic data were not available,
we used the week with the lowest case number between two waves. The specified calendar
periods are listed in Table S5. During later waves, multiple variants could initially co-circulate

before one became predominant. As a result, the estimated transmissibility tended to increase
before reaching a plateau (see, e.g., Fig 2C). In addition, in a previous study of the Delta
pandemic wave in India (43), we also observed that when many had been infected,
transmissibility could decrease a couple months after the peak, likely due to increased
reinfections for which onward transmission may be reduced. Thus, to obtain a more variant-
specific estimate, we computed the average transmissibility ($\overline{R_{TX}}$) using the weekly R_{TX}
estimates over the 8-week period starting the week prior to the maximal R_{tx} during each wave;
if no maximum existed (e.g. when a new variant is less transmissible), we simply averaged over
the entire wave. We then computed the change in transmissibility due to a given variant
relative to the ancestral SARS-CoV-2 as $(\frac{\overline{R_{TX,variant}} - \overline{R_{TX,ancestral}}}{\overline{R_{TX,ancestral}}}) \times 100\%$.
383
To quantify immune erosion, similar to ref (4), we estimated changes in susceptibility over time
and computed the change in immunity as $\Delta Imm = S_{t+1} - S_t + i_t$, where S_t is the susceptibility at
time-t and i_t is the new infections occurring during each week-t. We sum over all ΔImm
estimates for a particular location, during each wave, to compute the total change in immunity
due to a new variant, $\Sigma \Delta Imm_v$. We then computed the level of immune erosion as the ratio of
$\Sigma \Delta Imm_v$ to the model-estimated population immunity prior to the first detection of immune
erosion, during each wave. That is, as opposed to having a common reference of prior
immunity, here immune erosion for each variant depends on the state of the population
immune landscape – i.e., combining all prior exposures and vaccinations – immediately
preceding the surge of that variant.
394
395   For all provinces, model-inference was initiated the week starting March 15, 2020 and run
396   continuously until the week starting February 27, 2022. To account for model stochasticity, we
397   repeated the model-inference process 100 times for each province, each with 500 model
398   realizations and summarized the results from all 50,000 model estimates.
399

Model validation using independent data

To compare model estimates with independent observations not assimilated into the model-
inference system, we utilized three relevant datasets:
1)   Serological survey data measuring the prevalence of SARS-CoV-2 antibodies over time.
Multiple serology surveys have been conducted in different provinces of South Africa. The
South African COVID-19 Modelling Consortium summarizes the findings from several of
these surveys (see Fig 1A of ref (56)). We digitized all data presented in Fig 1A of ref (56)
and compared these to corresponding model-estimated cumulative infection rates
(computed mid-month for each corresponding month with a seroprevalence measure).
Due to unknown survey methodologies and challenges adjusting for sero-reversion and

reinfection, we used these data directly (i.e., without adjustment) for qualitative
comparison.
2) COVID-19-related hospitalization data, from COVID19ZA (35)/ We aggregated the total
number of COVID-19 hospital admissions during each wave and compared these
aggregates to model-estimated cumulative infection rates during the same wave. Of note,
these hospitalization data were available from June 6, 2020 onwards and are thus
incomplete for the first wave.
3) Age-adjusted excess mortality data from the South African Medical Research Council
(SAMRC)(20). Deaths due to COVID-19 (used in the model-inference system) are
undercounted. Thus, we also compared model-estimated cumulative infection rates to age-
adjusted excess mortality data during each wave. Of note, excess mortality data were
available from May 3, 2020 onwards and are thus incomplete for the first wave.
422
Model validation using retrospective prediction
As a fourth model validation, we generated model predictions at 2 or 1 week before the week
of highest cases for the Delta and Omicron waves, separately, and compared the predicted
cases and deaths to reported data unknown to the model. Predicting the peak timing, intensity,
and epidemic turnaround requires accurate estimation of model state variables and parameters
that determine future epidemic trajectories. This is particularly challenging for South Africa as
the pandemic waves tended to progress quickly such that cases surged to a peak in only 3 to 7
weeks. Thus, we chose to generate retrospective predictions 2 and 1 weeks before the peak of
cases in order to leverage 1 to 6 weeks of new variant data for estimating epidemiological
characteristics. Specifically, for each pandemic wave, we ran the model-inference system up to
2 weeks (or 1 week) before the observed peak of cases, halted the inference, and used the
population susceptibility and transmissibility of the circulating variant estimated at that time to
predict cases and deaths for the remaining weeks. Because the infection detection rate and
fatality risk are linked to observations of cases and deaths, changes of these quantities during
the prediction period could obscure the underlying infection rate and accuracy of the
prediction. Thus, for these two parameters specifically, we used model-inference estimates for
corresponding weeks to allow comparison of model-predicted cases and deaths with the data
while focusing on testing the accuracy of other key model estimates (e.g., transmissibility of the
new variant). As for the model-inference, we repeated each prediction 100 times, each with
500 model realizations and summarized the results from all 50,000 ensemble members.
443
444 **Data Availability:** All data used in this study are publicly available as described in the "Data
445 sources and processing" section.
446

447   **Code availability:** All source code and data necessary for the replication of our results and
448   figures will be made publicly available on Github.
449
450   **Acknowledgements**: This study was supported by the National Institute of Allergy and
451   Infectious Diseases (AI145883 and AI163023), the Centers for Disease Control and Prevention
452   (CK000592), and a gift from the Morris-Singer Foundation.
453
454   **Author contributions**: WY designed the study (main), conducted the model analyses,
455   interpreted results, and wrote the first draft. JS designed the study (supporting), interpreted
456   results, and critically revised the manuscript.
457
Competing interests: JS and Columbia University disclose partial ownership of SK Analytics. JS
discloses consulting for BNI.

Figure Legends:
Fig 1. Pandemic dynamics in South Africa, model-fit and validation using serology data. (A)
Pandemic dynamics in each of the nine provinces (see legend); dots depict reported weekly
numbers of cases and deaths; lines show model mean estimates (in the same color). (B) For
validation, model estimated infection rates are compared to seroprevalence measures over
time from multiple sero-surveys summarized in ref (56) (B). Boxplots depict the estimated
distribution for each province (middle bar = mean; edges = 50% CrIs) and whiskers (95% CrIs).
Red dots show corresponding measurements. Note that reported mortality was high in
February 2022 in some provinces with no clear explanation.
470

Fig 2. Model validation using retrospective prediction. Model-inference was trained on cases
and deaths data since March 15, 2020 up to 2 weeks (1st plot in each panel) or 1 week (2nd plot)
before the Delta or Omicron wave (see timing on the x-axis); the model was then integrated
forward using the estimates made at the time to predict cases (left panel) and deaths (right
panel) for the remaining weeks of each wave. Blue lines and surrounding shades show model
fitted cases and deaths for weeks before the prediction (line = median, dark blue area = 50%
CrIs, and light blue = 80% CrIs). Red lines show model projected median weekly cases and
deaths; surrounding shades show 50% (dark red) and 80% (light red) CIs of the prediction. For
comparison, reported cases and deaths for each week are shown by the black dots; however,
those to the right of the vertical dash lines (showing the start of each prediction) were not used
in the model. For clarity, here we show 80% CIs (instead of 95% CIs, which tend to be wider for
longer-term projections) and predictions for the four most populous provinces (Gauteng in A
and B; KwaZulu-Natal in C and D; Western Cape in E and F; and Eastern Cape in G and H).
Predictions for the other five provinces are shown in Fig S3.

Fig 3. Example model-inference estimates for Gauteng. (A) Observed relative mobility, vaccination rate, and estimated disease seasonal trend, compared to case and death rates over time. Key model-inference estimates are shown for the time-varying effective reproduction number R_t (B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and infection-fatality risk (F). Grey shaded areas indicate the approximate circulation period for each variant. In (B) – (F), blue lines and surrounding areas show the estimated mean, 50% (dark) and 95% (light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for estimated infection rates. *Note that the transmissibility estimates (in C) have removed the effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more stable than the reproduction number (R_t in B) and reflect changes in variant-specific properties. Also note that infection-fatality risk estimates were based on reported COVID-19 deaths and may not reflect true values due to likely under-reporting of COVID-19 deaths.*

Fig 4. Model-inferred epidemiological properties for different variants across SA provinces. Heatmaps show (A) Estimated mean infection rates by week (x-axis) and province (y-axis), (B) Estimated mean *cumulative* infection numbers relative to the population size in each province, and (C) Estimated population susceptibility (to the circulating variant) by week and province. (D) Boxplots in the top row show the estimated distribution of changes in transmissibility for Beta, Delta, and Omicron, relative to the Ancestral SARS-CoV-2, for each province (middle bar = median; edges = 50% CIs; and whiskers =95% CIs); boxplots in the bottom row show, for each variant, the estimated distribution of immune erosion to all adaptive immunity gained from infection and vaccination prior to that variant. Red lines show the mean across all provinces.

References:
1. Koelle K, Martin MA, Antia R, Lopman B, & Dean NE (2022) The changing epidemiology of SARS-CoV-2. *Science* 375(6585):1116-1121.
2. Tegally H*, et al.* (2021) Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* 592(7854):438-443.
3. Viana R*, et al.* (2022) Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*.
4. Yang W & Shaman J (2021) Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern. *Nature Communications* 12:5573.
5. Nyberg T*, et al.* (Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet*.
6. Wolter N*, et al.* (2022) Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *The Lancet* 399(10323):437-446.

7.   Madhi SA*, et al.* (2022) South African Population Immunity and Severe Covid-19 with
Omicron Variant. *medRxiv*:2021.2012.2020.21268096.
8.   Shinde V*, et al.* (2021) Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351
Variant. *N Engl J Med* 384(20):1899-1909.
9.   Garcia-Beltran WF*, et al.* (2021) Multiple SARS-CoV-2 variants escape neutralization by
vaccine-induced humoral immunity. *Cell* 184(9):2372-2383 e2379.
10.   Wall EC*, et al.* (2021) Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2
and B.1.351 by BNT162b2 vaccination. *Lancet*.
11.   Abu-Raddad LJ*, et al.* (2021) Severity, Criticality, and Fatality of the Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. *Clinical Infectious*
Diseases.
12.   Public Health England (2021) SARS-CoV-2 variants of concern and variants under
investigation in England. Technical briefing 14.
13.   Allen H*, et al.* (2021) Household transmission of COVID-19 cases associated with SARS-
CoV-2 delta variant (B.1.617.2): national case-control study. *The Lancet regional health.*
Europe:100252.
14.   Challen R*, et al.* (2021) Early epidemiological signatures of novel SARS-CoV-2 variants:
establishment of B.1.617.2 in England. *medRxiv*:2021.2006.2005.21258365.
15.   Earnest R*, et al.* (2021) Comparative transmissibility of SARS-CoV-2 variants Delta and
Alpha in New England, USA. *medRxiv*.
16.   Vohringer HS*, et al.* (2021) Genomic reconstruction of the SARS-CoV-2 epidemic in
England. *Nature*.
17.   Dhar MS*, et al.* (2021) Genomic characterization and epidemiology of an emerging SARS-
CoV-2 variant in Delhi, India. *Science*:eabj9932.
18.   Liu C*, et al.* (2021) Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and
convalescent serum. *Cell* 184(16):4220-+.
19.   de Oliveira T & Lessells R (2021) Update on Delta and other variants in South Africa and
other world.
20.   The South African Medical Research Council (SAMRC) (2021) Report on Weekly Deaths
in South Africa.
21.   Anonymous (South Africa Population (live).
22.   United States Census Bureau (2020) Census Bureau Releases 2020 Demographic Analysis
Estimates.
23.   Levin AT*, et al.* (2020) Assessing the age specificity of infection fatality rates for COVID-
19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol*
35(12):1123-1138.
24.   O'Driscoll M*, et al.* (2021) Age-specific mortality and immunity patterns of SARS-CoV-2.
Nature 590(7844):140-145.
25.   Anonymous (Variation in the COVID-19 infection-fatality ratio by age, time, and
geography during the pre-vaccine era: a systematic analysis. *The Lancet*.
26.   Garcia-Beltran WF*, et al.* (2022) mRNA-based COVID-19 vaccine boosters induce
neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* 185(3):457-466.e454.
27.   Hui KPY*, et al.* (2022) SARS-CoV-2 Omicron variant replication in human bronchus and
lung ex vivo. *Nature*.

28. Rössler A, Riepler L, Bante D, von Laer D, & Kimpel J (2022) SARS-CoV-2 Omicron Variant
Neutralization in Serum from Vaccinated and Convalescent Persons. *New England*
Journal of Medicine 386(7):698-700.
29. Cele S*, et al.* (2022) Omicron extensively but incompletely escapes Pfizer BNT162b2
neutralization. *Nature* 602(7898):654-656.
30. Brandal LT*, et al.* (2021) Outbreak caused by the SARS-CoV-2 Omicron variant in Norway,
November to December 2021. *Eurosurveillance* 26(50):2101147.
31. Helmsdal G*, et al.* (2022) Omicron outbreak at a private gathering in the Faroe Islands,
infecting 21 of 33 triple-vaccinated healthcare workers. *Clinical Infectious Diseases*.
32. van der Straten K*, et al.* (2022) Mapping the antigenic diversification of SARS-CoV-2.
medRxiv:2022.2001.2003.21268582.
33. Mao T*, et al.* (2022) Unadjuvanted intranasal spike vaccine booster elicits robust
protective mucosal immunity against sarbecoviruses. *bioRxiv*:2022.2001.2024.477597.
34. Morens DM, Taubenberger JK, & Fauci AS (2021) Universal Coronavirus Vaccines — An
Urgent Need. *New England Journal of Medicine* 386(4):297-299.
35. Data Science for Social Impact Research Group at University of Pretoria (2021)
Coronavirus COVID-19 (2019-nCoV) Data Repository for South Africa.
36. Iannone R (2020) Package 'stationaRy'.
37. Iannone R (2020) stationaRy.
38. Wallace J & Hobbs P (2006) *Atmospheric Science: An Introductory survey* (Academic
Press, New York) 2nd Edition Ed p 504.
39. Google Inc. (2020) Community Mobility Reports.
40. Anonymous (2020) Data on COVID-19 (coronavirus) vaccinations by Our World in Data.
41. Mathieu E*, et al.* (2021) A global database of COVID-19 vaccinations. *Nat Hum Behav*
5(7):947-953.
42. Department of Health Republic of South Africa (2021) Update on Covid-19 (Tuesday 23
November 2021).
43. Yang W & Shaman J (2021) COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta
variant, and implications for vaccination. *medRxiv*:2021.2006.2021.21259268.
44. Yang W, Shaff J, & Shaman J (2021) Effectiveness of non-pharmaceutical interventions to
contain COVID-19: a case study of the 2020 spring pandemic wave in New York City. *J R*
Soc Interface 18(175):20200822.
45. Lasry A*, et al.* (2020) Timing of Community Mitigation and Changes in Reported COVID-
19 and Community Mobility - Four U.S. Metropolitan Areas, February 26-April 1, 2020.
MMWR. Morbidity and mortality weekly report 69(15):451-457.
46. Kraemer MUG*, et al.* (2020) The effect of human mobility and control measures on the
COVID-19 epidemic in China. *Science* 368(6490):493-497.
47. Department of Health Republic of South Africa (2021) Latest Vaccine Statistics.
48. Abu-Raddad LJ, Chemaitelly H, & Butt AA (2021) Effectiveness of the BNT162b2 Covid-19
Vaccine against the B.1.1.7 and B.1.351 Variants. *New Engl J Med*.
49. Bernal JL*, et al.* (2021) Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta)
Variant. *New England Journal of Medicine* 385(7):585-594.
50. Andrews N*, et al.* (2021) Effectiveness of COVID-19 vaccines against the Omicron
(B.1.1.529) variant of concern. *medRxiv*:2021.2012.2014.21267615.

51.   Biryukov J, *et al.* (2020) Increasing Temperature and Relative Humidity Accelerates
613   Inactivation of SARS-CoV-2 on Surfaces. *mSphere* 5(4):e00441-00420.
614   52.   Morris DH, *et al.* (2021) Mechanistic theory predicts the effects of temperature and
615   humidity on inactivation of SARS-CoV-2 and other enveloped viruses. *Elife* 10.
616   53.   Yang W, *et al.* (2021) Estimating the infection-fatality risk of SARS-CoV-2 in New York
617   City during the spring 2020 pandemic wave: a model-based analysis. *The Lancet.*
618   *Infectious diseases* 21(2):203-212.
619   54.   Anderson JL (2001) An ensemble adjustment Kalman filter for data assimilation. *Mon.*
620   *Weather Rev.* 129(12):2884-2903.
621   55.   The National Institute for Communicable Diseases (NICD) of the National Health
622   Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa
623   (NGS-SA) (2021) Network for Genomic Surveillance South Africa (NGS-SA) SARS-CoV-2
624   Sequencing Update 19 August 2021.
625   56.   The South African COVID-19 Modelling Consortium (2021) COVID-19 modelling update:
626   Considerations for a potential fourth wave (17 Nov 2021).
627
628

  Fig 1. Pandemic dynamics in South Africa, model-fit and validation using serology data. (A)

  Pandemic dynamics in each of the nine provinces (see legend); dots depict reported weekly

  numbers of cases and deaths; lines show model mean estimates (in the same color). (B) For

  validation, model estimated infection rates are compared to seroprevalence measures over

  time from multiple sero-surveys summarized in ref (56) (B). Boxplots depict the estimated

  distribution for each province (middle bar = mean; edges = 50% CrIs) and whiskers (95% CrIs).

  Red dots show corresponding measurements. Note that reported mortality was high in

  February 2022 in some provinces with no clear explanation.

Fig 2. Model validation using retrospective prediction. Model-inference was trained on cases and deaths data since March 15, 2020 up to 2 weeks (1st plot in each panel) or 1 week (2nd plot) before the Delta or Omicron wave (see timing on the x-axis); the model was then integrated forward using the estimates made at the time to predict cases (left panel) and deaths (right panel) for the remaining weeks of each wave. Blue lines and surrounding shades show model fitted cases and deaths for weeks before the prediction (line = median, dark blue area = 50% CrIs, and light blue = 80% CrIs). Red lines show model projected median weekly cases and deaths; surrounding shades show 50% (dark red) and 80% (light red) CIs of the prediction. For comparison, reported cases and deaths for each week are shown by the black dots; however, those to the right of the vertical dash lines (showing the start of each prediction) were not used in the model. For clarity, here we show 80% CIs (instead of 95% CIs, which tend to be wider for longer-term projections) and predictions for the four most populous provinces (Gauteng in A and B; KwaZulu-Natal in C and D; Western Cape in E and F; and Eastern Cape in G and H). Predictions for the other five provinces are shown in Fig S3.

Fig 3. Example model-inference estimates for Gauteng. (A) Observed relative mobility,
vaccination rate, and estimated disease seasonal trend, compared to case and death rates over
time. Key model-inference estimates are shown for the time-varying effective reproduction
number R_t (B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and
infection-fatality risk (F). Grey shaded areas indicate the approximate circulation period for
each variant. In (B) – (F), blue lines and surrounding areas show the estimated mean, 50%
(dark) and 95% (light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for
estimated infection rates. *Note that the transmissibility estimates (in C) have removed the*
effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are
more stable than the reproduction number (R_t in B) and reflect changes in variant-specific
properties. Also note that infection-fatality risk estimates were based on reported COVID-19
deaths and may not reflect true values due to likely under-reporting of COVID-19 deaths.

Fig 4. Model-inferred epidemiological properties for different variants across SA provinces.
Heatmaps show (A) Estimated mean infection rates by week (x-axis) and province (y-axis), (B)
Estimated mean *cumulative* infection numbers relative to the population size in each province,
and (C) Estimated population susceptibility (to the circulating variant) by week and province.
(D) Boxplots in the top row show the estimated distribution of changes in transmissibility for
Beta, Delta, and Omicron, relative to the Ancestral SARS-CoV-2, for each province (middle bar =
median; edges = 50% CIs; and whiskers =95% CIs); boxplots in the bottom row show, for each
variant, the estimated distribution of immune erosion to all adaptive immunity gained from
infection and vaccination prior to that variant. Red lines show the mean across all provinces.

Supplemental Figures and Tables

Fig S1. Model-fit to case and death data in each province. Dots show reported SARS-CoV-2 cases and deaths by week. Blue lines and surrounding area show model estimated median, 50% (darker blue) and 95% (lighter blue) credible intervals. Note that reported mortality was high in February 2022 in some provinces with no clear explanation.

Fig S2. Model validation using hospitalization and excess mortality data. Model estimated
infection rates are compared to COVID-related hospitalizations (left panel) and excess mortality
(right panel) during the Ancestral (A), Beta (B), Delta (C), and Omicron (D) waves. Boxplots
show the estimated distribution for each province (middle bar = mean; edges = 50% CrIs) and
whiskers (=95% CrIs). Red dots show corresponding measurements. Correlation (*r*) between
model estimated cumulative infection rate and cumulative hospitalization or age-adjusted
excess mortality for each wave is shown in each plot. *Note that hospitalization data begin from*
6/6/20 and excess mortality data begin from 5/3/20 and thus are incomplete for the ancestral
wave.

693
694

Fig S3. Model validation using retrospective prediction, for the remaining 5 provinces. Model-inference was trained on cases and deaths data since March 15, 2020 up to 2 weeks (1st plot in each panel) or 1 week (2nd plot) before the Delta or Omicron wave (see timing on the x-axis); the model was then integrated forward using the estimates made at the time to predict cases (left panel) and deaths (right panel) for the remaining weeks of each wave. Blue lines and surrounding shades show model fitted cases and deaths for weeks before the prediction (line = median, dark blue area = 50% CrIs, and light blue = 80% CrIs). Red lines show model projected median weekly cases and deaths; surrounding shades show 50% (dark red) and 80% (light red) CIs of the prediction. For comparison, reported cases and deaths for each week are shown by the black dots; however, those to the right of the vertical dash lines (showing the start of each prediction) were not used in the model. For clarity, here we show 80% CIs (instead of 95% CIs, which tend to be wider for longer-term projections) and predictions for the five least populous provinces (Limpopo in A and B; Mpumalanga in C and D; North West in E and F; Free State in G and H; and Northern Cape in I and J). Predictions for the other 4 provinces are shown in Fig 2.

Fig S4. Model inference estimates for *KwaZulu-Natal*. (A) Observed relative mobility,
vaccination rate, and estimated disease seasonal trend, compared to case and death rates over
time. Key model-inference estimates are shown for the time-varying effective reproduction
number R_t (B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and
infection-fatality risk (F). Grey shaded areas indicate the approximate circulation period for
each variant. In (B) – (F), blue lines and surrounding areas show the estimated mean, 50%
(dark) and 95% (light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for
estimated infection rates. *Note that the transmissibility estimates (in C) have removed the*
effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are
more stable than the reproduction number (R_t in B) and reflect changes in variant-specific
properties. Also note that infection-fatality risk estimates were based on reported COVID-19
deaths and may not reflect true values due to likely under-reporting of COVID-19 deaths.

Fig S5. Model inference estimates for *Western Cape*. (A) Observed relative mobility,
vaccination rate, and estimated disease seasonal trend, compared to case and death rates over
time. Key model-inference estimates are shown for the time-varying effective reproduction
number R_t (B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and
infection-fatality risk (F). Grey shaded areas indicate the approximate circulation period for
each variant. In (B) – (F), blue lines and surrounding areas show the estimated mean, 50%
(dark) and 95% (light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for
estimated infection rates. *Note that the transmissibility estimates (in C) have removed the*
effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are
more stable than the reproduction number (R_t in B) and reflect changes in variant-specific
properties. Also note that infection-fatality risk estimates were based on reported COVID-19
deaths and may not reflect true values due to likely under-reporting of COVID-19 deaths.

Fig S6. Model inference estimates for *Eastern Cape*. (A) Observed relative mobility, vaccination
rate, and estimated disease seasonal trend, compared to case and death rates over time. Key
model-inference estimates are shown for the time-varying effective reproduction number R_t
(B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and infection-
fatality risk (F). Grey shaded areas indicate the approximate circulation period for each variant.
In (B) – (F), blue lines and surrounding areas show the estimated mean, 50% (dark) and 95%
(light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for estimated
infection rates. *Note that the transmissibility estimates (in C) have removed the effects of
changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more
stable than the reproduction number (R_t in B) and reflect changes in variant-specific properties.
Also note that infection-fatality risk estimates were based on reported COVID-19 deaths and
may not reflect true values due to likely under-reporting of COVID-19 deaths.*

Fig S7. Model inference estimates for *Limpopo*. (A) Observed relative mobility, vaccination
rate, and estimated disease seasonal trend, compared to case and death rates over time. Key
model-inference estimates are shown for the time-varying effective reproduction number R_t
(B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and infection-
fatality risk (F). Grey shaded areas indicate the approximate circulation period for each variant.
In (B) – (F), blue lines and surrounding areas show the estimated mean, 50% (dark) and 95%
(light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for estimated
infection rates. *Note that the transmissibility estimates (in C) have removed the effects of*
changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more
stable than the reproduction number (R_t in B) and reflect changes in variant-specific properties.
Also note that infection-fatality risk estimates were based on reported COVID-19 deaths and
may not reflect true values due to likely under-reporting of COVID-19 deaths.

Fig S8. Model inference estimates for *Mpumalanga*. (A) Observed relative mobility,
vaccination rate, and estimated disease seasonal trend, compared to case and death rates over
time. Key model-inference estimates are shown for the time-varying effective reproduction
number R_t (B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and
infection-fatality risk (F). Grey shaded areas indicate the approximate circulation period for
each variant. In (B) – (F), blue lines and surrounding areas show the estimated mean, 50%
(dark) and 95% (light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for
estimated infection rates. *Note that the transmissibility estimates (in C) have removed the*
effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are
more stable than the reproduction number (R_t in B) and reflect changes in variant-specific
properties. Also note that infection-fatality risk estimates were based on reported COVID-19
deaths and may not reflect true values due to likely under-reporting of COVID-19 deaths.

Fig S9. Model inference estimates for *North West*. (A) Observed relative mobility, vaccination
rate, and estimated disease seasonal trend, compared to case and death rates over time. Key
model-inference estimates are shown for the time-varying effective reproduction number R_t
(B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and infection-
fatality risk (F). Grey shaded areas indicate the approximate circulation period for each variant.
In (B) – (F), blue lines and surrounding areas show the estimated mean, 50% (dark) and 95%
(light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for estimated
infection rates. *Note that the transmissibility estimates (in C) have removed the effects of*
changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more
stable than the reproduction number (R_t in B) and reflect changes in variant-specific properties.
Also note that infection-fatality risk estimates were based on reported COVID-19 deaths and
may not reflect true values due to likely under-reporting of COVID-19 deaths.

Fig S10. Model inference estimates for *Free State*. (A) Observed relative mobility, vaccination rate, and estimated disease seasonal trend, compared to case and death rates over time. Key model-inference estimates are shown for the time-varying effective reproduction number R_t (B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and infection-fatality risk (F). Grey shaded areas indicate the approximate circulation period for each variant. In (B) – (F), blue lines and surrounding areas show the estimated mean, 50% (dark) and 95% (light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for estimated infection rates. *Note that the transmissibility estimates (in C) have removed the effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more stable than the reproduction number (R_t in B) and reflect changes in variant-specific properties. Also note that infection-fatality risk estimates were based on reported COVID-19 deaths and may not reflect true values due to likely under-reporting of COVID-19 deaths.*

Fig S11. Model inference estimates for *Northern Cape*. (A) Observed relative mobility,
vaccination rate, and estimated disease seasonal trend, compared to case and death rates over
time. Key model-inference estimates are shown for the time-varying effective reproduction
number R_t (B), transmissibility (C), population susceptibility (D), infection-detection rate (E), and
infection-fatality risk (F). Grey shaded areas indicate the approximate circulation period for
each variant. In (B) – (F), blue lines and surrounding areas show the estimated mean, 50%
(dark) and 95% (light) CrIs; boxes and whiskers show the estimated mean, 50% and 95% CrIs for
estimated infection rates. *Note that the transmissibility estimates (in C) have removed the*
effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are
more stable than the reproduction number (R_t in B) and reflect changes in variant-specific
properties. Also note that infection-fatality risk estimates were based on reported COVID-19
deaths and may not reflect true values due to likely under-reporting of COVID-19 deaths.

Table S1. Model estimated infection-detection rate during each wave. Numbers show the estimated percentage of infections (including asymptomatic and subclinical infections) documented as cases (mean and 95% CI in parentheses).

Province	Ancestral wave	Beta wave	Delta wave	Omicron wave
Gauteng	4.59 (2.62, 9.77)	6.18 (3.29, 11.11)	6.27 (3.44, 12.39)	4.16 (2.46, 9.72)
KwaZulu-Natal	4.33 (2.01, 11.02)	7.4 (3.89, 13.67)	5.69 (2.69, 12.34)	3.25 (1.84, 7.81)
Western Cape	5.62 (3, 10.93)	7.1 (3.99, 12.78)	6.83 (3.71, 13.08)	4.26 (2.49, 9.37)
Eastern Cape	3.79 (1.98, 9.39)	6.1 (3.35, 11.27)	5.58 (2.63, 11.52)	2.91 (1.4, 7.99)
Limpopo	2.13 (0.79, 6.46)	4.57 (1.89, 10.01)	3.4 (1.53, 9.3)	2.9 (1.2, 7.55)
Mpumalanga	3.42 (1.42, 9.1)	6.28 (2.85, 12.51)	5.71 (2.58, 12.96)	3.13 (1.54, 7.24)
North West	3.37 (1.62, 7.88)	5.79 (2.77, 11.14)	5.26 (2.8, 10.8)	3.73 (1.78, 8.62)
Free State	5.02 (2.83, 10.63)	6.69 (3.69, 11.97)	6.5 (3.16, 13.23)	4.03 (2.12, 8.95)
Northern Cape	4.96 (2.75, 10.34)	6.49 (3.72, 11.44)	6.69 (3.74, 12.32)	3.71 (1.97, 8.21)

Table S2. Model estimated attack rate during each wave. Numbers show estimated cumulative infection numbers, expressed as percentage of population size (mean and 95% CI in parentheses).

Province	Ancestral wave	Beta wave	Delta wave	Omicron wave
Gauteng	32.83 (15.42, 57.59)	21.87 (12.16, 41.13)	49.82 (25.22, 90.79)	44.49 (19.01, 75.3)
KwaZulu-Natal	24.06 (9.45, 51.91)	26.36 (14.28, 50.18)	27.15 (12.52, 57.39)	38.11 (15.87, 67.56)
Western Cape	28.44 (14.61, 53.17)	37.09 (20.61, 66.04)	47.29 (24.68, 87.1)	44.1 (20.02, 75.4)
Eastern Cape	32.85 (13.27, 62.95)	27.44 (14.86, 49.95)	25.59 (12.4, 54.34)	26.38 (9.59, 54.69)
Limpopo	13.78 (4.55, 37.21)	17.12 (7.82, 41.41)	28.22 (10.33, 62.74)	18.62 (7.15, 45.01)
Mpumalanga	18.99 (7.14, 45.83)	17.33 (8.7, 38.21)	27.18 (11.97, 60.14)	27.67 (11.96, 56.13)
North West	24.57 (10.51, 51.09)	16.04 (8.34, 33.49)	37.21 (18.13, 70.02)	26.17 (11.33, 54.71)
Free State	39.31 (18.54, 69.57)	24.23 (13.54, 43.92)	30.85 (15.16, 63.38)	32.79 (14.76, 62.32)
Northern Cape	34.92 (16.77, 63.13)	26.98 (15.3, 47.09)	55.59 (30.18, 99.32)	36.87 (16.65, 69.34)

Table S3. Model estimated infection-fatality risk during each wave. Numbers are percentages (%; mean and 95% CI in parentheses). Note that these estimates were based on reported COVID-19 deaths and may be biased due to likely under-reporting of COVID-19 deaths.

Province	Ancestral wave	Beta wave	Delta wave	Omicron wave
Gauteng	0.09 (0.05, 0.2)	0.19 (0.1, 0.33)	0.11 (0.06, 0.21)	0.03 (0.02, 0.06)
KwaZulu-Natal	0.09 (0.04, 0.24)	0.27 (0.14, 0.49)	0.14 (0.06, 0.29)	0.03 (0.02, 0.08)
Western Cape	0.21 (0.11, 0.41)	0.3 (0.17, 0.54)	0.25 (0.14, 0.48)	0.06 (0.04, 0.14)
Eastern Cape	0.11 (0.06, 0.27)	0.5 (0.27, 0.91)	0.2 (0.1, 0.42)	0.08 (0.04, 0.22)
Limpopo	0.06 (0.02, 0.17)	0.18 (0.08, 0.4)	0.1 (0.04, 0.27)	0.05 (0.02, 0.12)
Mpumalanga	0.07 (0.03, 0.18)	0.1 (0.05, 0.2)	0.04 (0.02, 0.1)	0.21 (0.11, 0.5)
North West	0.05 (0.02, 0.11)	0.21 (0.1, 0.4)	0.16 (0.08, 0.32)	0.05 (0.03, 0.12)
Free State	0.13 (0.08, 0.28)	0.42 (0.23, 0.75)	0.26 (0.13, 0.52)	0.09 (0.05, 0.2)
Northern Cape	0.06 (0.03, 0.13)	0.21 (0.12, 0.37)	0.17 (0.1, 0.32)	0.22 (0.12, 0.48)

Table S4. Prior ranges for the parameters used in the model-inference system. All initial values are drawn from uniform distributions using Latin Hypercube Sampling.

Parameter/ variable	Symbol	Prior range	Source/rationale
Initial exposed	$E(t=0)$	1 – 500 times of reported cases during the Week of March 15, 2020 for Western Cape and Eastern Cape; 1 – 10 times of reported cases during the Week of March 15, 2020, for other provinces	Low infection-detection rate in first weeks; earlier and higher case numbers reported in Western Cape and Eastern Cape than other provinces.
Initial infectious	$I(t=0)$	Same as for $E(t=0)$	
Initial susceptible	$S(t=0)$	99 – 100% of the population	Almost everyone is susceptible initially
Population size	N	N/A	Based on population data from COVID19ZA (main text ref 24)
Variant-specific transmission rate	β	For all provinces, starting from U[0.4, 0.7] at time 0 and allowed to increase over time using space re-probing(1) with values drawn from U[0.5, 0.9] during the Beta wave, U[0.7, 1.25] during the Delta wave, and U[0.7, 1.3] during the Omicron wave.	For the initial range at model initialization, based on R_0 estimates of around 1.5-4 for SARS-CoV-2.(2-4) For the Beta, Delta and Omicron variants, we use large bounds for space re-probing (SR)(1) to explore the parameter state space and enable estimation of changes in transmissibility due to the new variants. Note that SR is only applied to 3-10% of the ensemble members and β can migrate outside either the initial range or the SR ranges during EAKF update.
Scaling of effectiveness of NPI	e	[0.5, 1.5], for all provinces	Around 1, with a large bound to be flexible.

Latency period	Z	[2, 5] days, for all provinces	Incubation period: 5.2 days (95% CI: 4.1, 7)(2); latency period is likely shorter than the incubation period
Infectious period	D	[2, 5] days, for all provinces	Time from symptom onset to hospitalization: 3.8 days (95% CI: 0, 12.0) in China,(5) plus 1-2 days viral shedding before symptom onset. We did not distinguish symptomatic/asymptomatic infections.
Immunity period	L	[730, 1095] days, for all provinces	Assuming immunity lasts for 2-3 years
Mean of time from viral shedding to diagnosis	T_m	[5, 8] days, for all provinces	From a few days to a week from symptom onset to diagnosis/reporting,(5) plus 1-2 days of viral shedding (being infectious) before symptom onset.
Standard deviation (SD) of time from viral shedding to diagnosis	T_{sd}	[1, 3] days, for all provinces	To allow variation in time to diagnosis/reporting
Infection-detection rate	r	Starting from U[0.001, 0.01] at time 0 for Western Cape and Eastern Cape as these two provinces had earlier and higher case numbers during March – April 2020 than other provinces, suggesting lower detection rate at the time; for the rest starting from U[0.01, 0.06]. For all provinces,	Large uncertainties; therefore, in general we use large prior bounds and large bounds for space re-probing (SR). Note that SR is only applied to 3-10% of the ensemble members and r can migrate

	allowed *r* to increase over time using space re-probing (1) with values drawn from uniform distributions with ranges between roughly 0.01 to 0.12.	outside either the initial range or the SR ranges during EAKF update.
Infection fatality risk (IFR)	For Gauteng: starting from [0.0001, 0.002] at time 0 and allowed to change over time using space re-probing(1) with values drawn from U[0.0001, 0.005] during 12/13/2020 – 5/15/21 (due to Beta), U[0.0001, 0.002] during the Delta wave, and U[0.00001, 0.00075] starting 9/1/21 (Omicron wave). For KwaZulu-Natal: starting from U[0.0001, 0.003] at time 0 and allowed to change over time using space re-probing (1) with values drawn from U[0.0001, 0.005] during 4/19/20 –10/31/20 (ancestral wave), U[0.0001, 0.01] during 11/1/20 – 5/15/21 (Beta wave), U[0.0001, 0.002] during the Delta wave, and U[0.00001, 0.00075] starting 10/1/21 (Omicron wave). For Western Cape: starting from U[0.00001, 0.003] at time 0 and allowed to change over time using space re-probing (1) with values drawn from U[0.00001, 0.0004] during 4/19/20 – 10/31/20 (ancestral wave), U[0.00001, 0.01] during 11/1/20 – 5/15/21 (Beta wave), U[0.00001, 0.005] during 5/16/21 – 9/30/21 (Delta wave) and U[0.00001, 0.002] starting 10/1/21 (Omicron wave). For Eastern Cape: starting from U[0.0001, 0.003] at time 0 and allowed to change over time using space re-probing(1) with values drawn from U[0.0001, 0.004] during 4/19/20 – 9/30/20 (Ancestral wave), U[0.0001, 0.01] during 10/1/20 – 40/30/21 (Beta wave), [0.0001, 0.005] during the Delta wave, and U[0.00001, 0.002] or starting 10/16/21 (Omicron wave).	Based on previous estimates(6) but extend to have wider ranges. Note that SR is only applied to 3-10% of the ensemble members and IFR can migrate outside either the initial range or the SR ranges during EAKF update. Western Cape had earlier and higher case numbers during March – April 2020 than other provinces, suggesting lower detection rate at the time. Initial mortality rate in Gauteng was relatively low because initial infections occurred mainly among middle-aged, returning holiday makers.(7) Earlier spread of Beta in Eastern Cape, KwaZulu-Natal, and Northern Cape, higher numbers of deaths per capita reported. Free State reported higher number of deaths per capita.

For Limpopo and Mpumalanga: starting from U[0.0001, 0.003] at time 0 and allowed to change over time using space re-probing (1) with values drawn from U[0.0001, 0.01] during the Beta wave, U[0.0001, 0.005] during the Delta wave, U[0.00001, .002] for the Omicron wave.
For Free State: starting from U[0.0001, 0.003] at time 0 and allowed to change over time using space re-probing (1) with values drawn from U[0.0001, 0.006] during 3/16/20 – 10/31/20, U[0.0001, 0.01] during the Beta wave, U[0.0001, 0.008] during the Delta wave, and U[0.00001, 0.002] starting 10/1/21 (Omicron wave).
For North West and Northern Cape: starting from U[0.0001, 0.003] at time 0 and allowed to change over time using space re-probing (1) with values drawn from U[0.0001, 0.005] during the Beta wave, U[0.0001, 0.003] during the Delta wave, and U[0.00001, 0.0015] starting 10/1/21 (Omicron wave).

References including in Table S4:
1.   Yang W & Shaman J (2014) A simple modification for improving inference of non-linear dynamical systems. *arXiv*:1403.6804.
2.   Li Q*, et al.* (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New Engl J Med*.
3.   Wu JT, Leung K, & Leung GM (2020) Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet*.
4.   Li R*, et al.* (2020) Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* 368(6490):489-493.
5.   Zhang J*, et al.* (2020) Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *The Lancet. Infectious diseases*.
6.   Verity R*, et al.* (2020) Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet. Infectious diseases*.
7.   Giandhari J*, et al.* (2021) Early transmission of SARS-CoV-2 in South Africa: An epidemiological and phylogenetic report. *Int J Infect Dis* 103:234-241.

Table S5. Approximate epidemic timing (mm/dd/yy) for each wave in each province, used in the study. Note 3/5/22 is the last date of the study period.

Province	Variant	Start date	End date
Gauteng	Ancestral	3/15/20	10/31/20
Gauteng	Beta	11/1/20	5/15/21
Gauteng	Delta	5/16/21	8/31/21
Gauteng	Omicron	9/1/21	3/5/22
KwaZulu-Natal	Ancestral	3/15/20	9/15/20
KwaZulu-Natal	Beta	9/16/20	5/15/21
KwaZulu-Natal	Delta	5/16/21	9/30/21
KwaZulu-Natal	Omicron	10/1/21	3/5/22
Western Cape	Ancestral	3/15/20	9/15/20
Western Cape	Beta	9/16/20	5/15/21
Western Cape	Delta	5/16/21	9/30/21
Western Cape	Omicron	10/1/21	3/5/22
Eastern Cape	Ancestral	3/15/20	8/15/20
Eastern Cape	Beta	8/16/20	4/30/21
Eastern Cape	Delta	5/1/21	10/15/21
Eastern Cape	Omicron	10/16/21	3/5/22
Limpopo	Ancestral	3/15/20	10/31/20
Limpopo	Beta	11/1/20	5/15/21
Limpopo	Delta	5/16/21	9/30/21
Limpopo	Omicron	10/1/21	3/5/22
Mpumalanga	Ancestral	3/15/20	10/31/20
Mpumalanga	Beta	11/1/20	5/15/21
Mpumalanga	Delta	5/16/21	9/30/21
Mpumalanga	Omicron	10/1/21	3/5/22
North West	Ancestral	3/15/20	10/31/20
North West	Beta	11/1/20	5/15/21
North West	Delta	5/16/21	9/30/21
North West	Omicron	10/1/21	3/5/22
Free State	Ancestral	3/15/20	10/31/20
Free State	Beta	11/1/20	5/31/21
Free State	Delta	6/1/21	9/30/21
Free State	Omicron	10/1/21	3/5/22
Northern Cape	Ancestral	3/15/20	10/31/20
Northern Cape	Beta	11/1/20	5/15/21
Northern Cape	Delta	5/16/21	9/30/21
Northern Cape	Omicron	10/1/21	3/5/22